Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 study
LIVER CANCER. 2023
Erscheinungsjahr: 2023
Publikationstyp: Zeitschriftenaufsatz
| Geprüft | Bibliothek |
Autoren
Kudo, Masatoshi (Autor)
Tsuchiya, Kaoru (Autor)
Shao, Yu-Yun (Autor)
Finn, Richard S. (Autor)
Galle, Peter R. (Autor)
Ducreux, Michel (Autor)
Cheng, Ann-Lii (Autor)
Yamashita, Tatsuya (Autor)
Koga, Hironori (Autor)
Take, Ryosuke (Autor)
Yamada, Kyoko (Autor)
Asakawa, Takashi (Autor)
Nakagawa, Yuki (Autor)
Ikeda, Masafumi (Autor)
Klassifikation
DDC Sachgruppe:
Medizin
